

CITATION REPORT

List of articles citing

Development of an HPLC-MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study

DOI: 10.4155/bio-2018-0129
Bioanalysis, 2018, 10, 1439-1454.

Source: <https://exaly.com/paper-pdf/70659410/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2316-2324	6.7	0
4	Bioanalytical methods for quantification of novel sodium-glucose cotransporter 2 inhibitors: toward greener approach in separation science. <i>Bioanalysis</i> , 2020 , 12, 565-568	2.1	0
3	Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 147, 105281	5.1	2
2	Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes. <i>Current Diabetes Reviews</i> , 2021 ,	2.7	0
1	Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. 2022 , 179, 106298		0